How Much Does Actos (Pioglitazone) Cost in Wyoming in 2026?

Wyoming Retail Pharmacy Prices for Pioglitazone in 2026

Generic pioglitazone costs an average of $15 per month at Wyoming retail pharmacies when paying cash, making it one of the more affordable oral diabetes medications available. Brand-name Actos carries a list price near $60 per month from Takeda, but very few pharmacies dispense the brand when generics are stocked.

Prices vary by pharmacy and location across Wyoming's 23 counties. Larger chain pharmacies in Cheyenne, Casper, and Laramie tend to cluster near that $15 average. Rural independent pharmacies may charge slightly more due to lower dispensing volume and higher wholesale acquisition costs. A 90-day supply purchased through mail-order pharmacy services often drops the per-month cost below $12.

Pioglitazone belongs to the thiazolidinedione (TZD) class of insulin sensitizers. The FDA approved pioglitazone in 1999 as an adjunct to diet and exercise for type 2 diabetes. Generic versions entered the market in August 2012 after Takeda's patent expired, and competition among generic manufacturers drove prices down sharply. That price erosion is the reason Wyoming residents can now fill a month's supply for roughly the cost of a fast-food meal.

The PIVENS trial (N=247) published in the New England Journal of Medicine demonstrated that pioglitazone 30 mg daily produced significant histological improvement in nonalcoholic steatohepatitis compared with placebo over 96 weeks, with 34% of pioglitazone-treated patients achieving the primary endpoint versus 19% on placebo 1. This trial expanded clinical interest in pioglitazone beyond glucose control, though the NASH indication remains off-label.

Wyoming Medicaid and Pioglitazone Coverage

Wyoming Medicaid does not cover pioglitazone as of 2026. Patients enrolled in Wyoming's fee-for-service Medicaid program or the Wyoming Department of Health's managed care arrangements will not find Actos or generic pioglitazone on the preferred drug list.

This gap matters. Wyoming has one of the smallest Medicaid populations in the country, with roughly 80,000 enrollees, yet type 2 diabetes prevalence in the state sits near 9% according to CDC diabetes surveillance data. Medicaid enrollees who need an insulin sensitizer typically get directed toward metformin first, which Wyoming Medicaid does cover at preferred-tier status. For patients who cannot tolerate metformin or who have contraindications such as an estimated GFR below 30 mL/min, the lack of pioglitazone coverage creates a treatment gap.

Providers can submit a prior authorization request to Wyoming Medicaid arguing medical necessity. Approval is not guaranteed. The prior authorization process requires documentation of metformin intolerance or contraindication, and the turnaround window is typically 72 hours for non-urgent requests. Even when approved, the reimbursement rate may leave the patient with a copay.

At $15 per month cash, some Medicaid patients find it cheaper to pay out of pocket rather than pursue the prior authorization pathway. This is an unusual situation where the cash price undercuts the administrative burden of insurance billing.

Commercial Insurance and Medicare Part D in Wyoming

Most commercial insurance plans available on the Wyoming Health Insurance Marketplace include generic pioglitazone on their formularies. Blue Cross Blue Shield of Wyoming, the dominant commercial carrier in the state, lists generic pioglitazone as a Tier 1 or Tier 2 drug depending on the specific plan. Typical copays range from $0 to $15 for a 30-day supply at preferred pharmacies.

Medicare Part D plans in Wyoming also generally cover generic pioglitazone. Under the Inflation Reduction Act provisions that took effect in 2025, Medicare beneficiaries now have a $2,000 annual out-of-pocket cap on Part D drug spending. For a medication costing $15 per month at retail, the Part D copay is often $1 to $5, and the annual spend on pioglitazone alone would not approach the catastrophic threshold.

Wyoming's insurance market is small. Only two or three carriers participate on the ACA exchange in most counties, which limits plan choice but also means formulary checking is straightforward. Patients can verify coverage through their plan's online formulary tool or by calling the number on the back of their insurance card. Pharmacists in Wyoming can also run a test claim at the point of sale to confirm tier status and copay amount before dispensing.

The American Association of Clinical Endocrinology (AACE) 2023 consensus algorithm positions pioglitazone as a second-line or third-line agent after metformin and SGLT2 inhibitors or GLP-1 receptor agonists, which influences how insurers tier the drug. Because it sits behind newer, more expensive agents in the treatment hierarchy, insurers have little reason to restrict a $15-per-month generic.

Compounded Pioglitazone in Wyoming

Compounded pioglitazone is legal in Wyoming through 503A-licensed compounding pharmacies. A 503A pharmacy operates under a patient-specific prescription from a licensed prescriber, as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act.

The practical question is whether compounding makes sense for pioglitazone. At $15 per month for commercially manufactured generic tablets, the cost argument for compounding is weak. Compounding becomes relevant in specific clinical scenarios: a patient who needs a dose not commercially available (say, 7.5 mg for NASH titration), a patient who cannot swallow tablets and needs a liquid suspension, or a patient with an allergy to an inactive ingredient in the manufactured product.

Wyoming has a limited number of 503A compounding pharmacies, concentrated in Cheyenne and Casper. Patients in rural areas can legally receive compounded pioglitazone by mail from any state-licensed 503A pharmacy that ships to Wyoming, provided the prescription originates from a Wyoming-licensed or reciprocally licensed prescriber.

The Wyoming Board of Pharmacy oversees compounding pharmacy licensure within the state. Any out-of-state pharmacy shipping compounded medications into Wyoming must hold a nonresident pharmacy license. Patients should verify that their compounding pharmacy holds appropriate licensure before filling a prescription.

Telehealth Prescribing of Pioglitazone in Wyoming

Wyoming permits telehealth prescribing of pioglitazone. The state's telehealth parity law, updated in 2021, requires that insurers cover telehealth visits at the same rate as in-person visits. A provider licensed in Wyoming can evaluate a patient via video or audio-only visit and prescribe pioglitazone if clinically appropriate.

This matters for access. Wyoming is the least populated state, with roughly 577,000 residents spread across 97,813 square miles. Endocrinologists are scarce outside of Cheyenne and Casper. Many Wyoming residents with type 2 diabetes receive care from primary care providers or family medicine physicians, and telehealth extends the reach of the limited endocrinology workforce.

Pioglitazone does require baseline and periodic monitoring that may need in-person components. The FDA prescribing information recommends liver function testing (ALT) before initiation and periodically thereafter, given historical concerns about hepatotoxicity with the older TZD troglitazone (withdrawn in 2000). A prescriber can order labs remotely and review results via telehealth, so the monitoring requirement does not preclude telehealth management.

Patients using telehealth platforms should confirm that the prescriber holds an active Wyoming medical license or practices under an interstate compact that Wyoming recognizes. The prescription can be sent electronically to any Wyoming retail or mail-order pharmacy.

Discount Programs and Savings Strategies

Several pathways exist to reduce pioglitazone costs below the $15 Wyoming average.

Generic manufacturer discount cards. Multiple generic pioglitazone manufacturers participate in pharmacy benefit manager discount networks. GoodRx, RxSaver, and similar aggregator platforms frequently show Wyoming prices between $4 and $10 for a 30-day supply of pioglitazone 30 mg or 45 mg. These prices are available at major chains including Walmart, Walgreens, and Albertsons locations across Wyoming.

Walmart $4 list. Pioglitazone has historically appeared on Walmart's $4 generic program for a 30-day supply. Wyoming has Walmart Supercenters in Cheyenne, Casper, Gillette, Rock Springs, Sheridan, Riverton, and other cities, providing broad geographic access to this pricing.

Takeda savings programs. Takeda, the brand manufacturer of Actos, has periodically offered savings cards for brand-name Actos. These cards typically reduce the patient's copay to a set dollar amount, often $0 to $15 for commercially insured patients. The savings card does not apply to government insurance (Medicare, Medicaid, Tricare). Given that generic pioglitazone already costs $15 or less, the Takeda card is mainly useful for the rare patient whose insurance specifically requires the brand product.

Patient assistance programs. Takeda's patient assistance program, Takeda Help at Hand, provides free medication to uninsured patients who meet income eligibility requirements, generally at or below 250% of the federal poverty level. Wyoming residents can apply through the program's website or by calling the assistance line. Processing typically takes two to four weeks.

340B pricing. Wyoming has several 340B-eligible entities, including community health centers in underserved areas. Patients who receive care at a 340B-covered entity may access pioglitazone at significantly reduced cost, sometimes $0, depending on the entity's pharmacy arrangement. The Health Resources and Services Administration (HRSA) maintains the 340B database where patients can search for covered entities in their area.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has noted: "Access to affordable diabetes medications is a fundamental component of diabetes management, and generic availability of drugs like pioglitazone has meaningfully reduced cost barriers for patients across the country" 2. The ADA's 2024 Standards of Care explicitly includes cost as a factor in medication selection, positioning inexpensive generics like pioglitazone favorably for cost-sensitive patients.

Pioglitazone Dosing and What to Expect

Pioglitazone is taken once daily, with or without food. Starting doses are typically 15 mg or 30 mg, with a maximum of 45 mg daily. The glucose-lowering effect takes 2 to 4 weeks to become apparent, and full effect may require 8 to 12 weeks. This slow onset reflects the drug's mechanism: pioglitazone activates PPAR-gamma receptors in adipose tissue, muscle, and liver, improving insulin sensitivity at the cellular level rather than stimulating insulin secretion.

Common side effects include weight gain (typically 2 to 4 kg over the first year), peripheral edema, and an increased risk of bone fractures, particularly in postmenopausal women. A meta-analysis published in the BMJ found that pioglitazone was associated with a 1.4-fold increased risk of bladder cancer, though subsequent analyses including the 10-year Kaiser Permanente study have shown conflicting results, and the absolute risk increase, if real, is small. The FDA added a boxed warning for congestive heart failure risk; pioglitazone is contraindicated in NYHA Class III or IV heart failure.

Monitoring requirements are manageable. Baseline ALT, a complete metabolic panel, and a clinical assessment for heart failure symptoms should precede initiation. Follow-up labs at 3 months and then annually are standard practice.

Comparing Pioglitazone to Other Diabetes Drugs in Wyoming

At $15 per month, pioglitazone is among the cheapest diabetes medications available in Wyoming. Metformin is cheaper (often $4 per month for generic). Sulfonylureas like glipizide run $4 to $10. But newer agents cost dramatically more: brand-name semaglutide (Ozempic) lists above $900 per month, and SGLT2 inhibitors like empagliflozin (Jardiance) list near $550 before insurance.

The cost differential matters for uninsured or underinsured Wyoming residents. The Endocrine Society's clinical practice guideline on type 2 diabetes pharmacotherapy acknowledges that medication cost is a legitimate consideration in treatment selection and that TZDs remain a valid option when GLP-1 receptor agonists or SGLT2 inhibitors are not affordable or tolerated.

For the Wyoming patient paying cash, pioglitazone offers A1C reduction of 1.0% to 1.5% (per the ADA Standards of Care) at a fraction of the cost of newer branded alternatives, with the added potential benefit of hepatic fat reduction relevant to NASH [1].